EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Stage-dependent tau-PET signatures in Huntington’s disease revealed by [¹⁸F]PI-2620

Saul Martinez-Horta, Jesus Perez-Perez, Arnau Puig-Davi, Valle Camacho, Laura Perez-Carasol, Carla Franch-Marti, Gonzalo Olmedo-Saura, Alex Fernandez-Leon, Albert Flotats, Guilherme D Kolinger, Santiago Bullich, Esther Perez-Martinez und 2 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-08003-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Saul Martinez-Horta und 13 weiteren Autor:innen. Beteiligte Einrichtung: Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, 08041, Spain. Hauptthemen laut MEDLINE: Huntington Disease, Positron-Emission Tomography, tau Proteins, Thiazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundació Institució dels Centres de Recerca de Catalunya.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Neuropathological and biomarker evidence implicates tau dysregulation as a downstream component of Huntington’s disease (HD) pathobiology, yet its in vivo distribution has not been characterised using second-generation tau-PET tracers. We aimed to define the regional organisation, stage dependence and clinical relevance of tau-sensitive PET signal across the HD disease spectrum.

Methods

Fifty-four participants (13 healthy controls, 9 premanifest mutation carriers and 32 manifest carriers) underwent 60-minute dynamic [¹⁸F]PI-2620 PET imaging. Tau-PET signal was quantified using distribution volume ratios (DVR) derived from reference-tissue kinetic modelling. Analyses combined region-of-interest and whole-brain mapping with threshold-based positivity profiling, modelling of cumulative genetic disease burden (CAP), and clinico-anatomical association analyses.

Results

Tau-PET abnormalities showed a spatially ordered pattern dominated by subcortical involvement. The globus pallidus exhibited the strongest effect, with marked DVR increases and high positivity rates emerging in premanifest carriers and approaching saturation in manifest HD. Additional subcortical changes involved the putamen, whereas caudate DVR decreased in manifest disease. Cortical effects were more modest and selectively involved posterior associative regions. CAP modelling supported predominantly monotonic subcortical stage-related profiles, while limbic and cortical regions showed heterogeneous cross-sectional patterns. Clinico-anatomical analyses linked subcortical tau-PET signal with genetic burden and motor severity and limbic signal with psychiatric symptoms.

Conclusion

Tau-sensitive PET signal represents a spatially ordered and stage-dependent feature of HD and identifies a reproducible pallidal signature linked to disease burden, supporting its potential as a biomarker for patient stratification and mechanistic monitoring in therapeutic studies targeting downstream pathological processes. Trial registration number NCT07503743.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntington DiseasePositron-Emission Tomographytau ProteinsThiazolesHumansFemaleMaleMiddle AgedAdultCase-Control StudiesBrainFluorine RadioisotopesPyridines

Stichwörter der Autor:innen

Disease stageHuntington’s diseaseKinetic modellingNeurodegenerationTau PET[¹⁸F]PI-2620

Substanzen

tau Proteins((18)F)PI-2620ThiazolesPI-2620Fluorine RadioisotopesPyridines

Autor:innen und Institutionen

  • Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, 08041, Spain.
  • Research Institute Sant Pau (IR-Sant Pau), Centre CERCA, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
  • Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain.
  • European Huntington's Disease Network (EHDN), Ulm, Germany.
  • Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Förderung

  • Fundació Institució dels Centres de Recerca de Catalunya

Zitieren

APA

Martinez-Horta, S., Perez-Perez, J., Puig-Davi, A., Camacho, V., Perez-Carasol, L., Franch-Marti, C., Olmedo-Saura, G., Fernandez-Leon, A., Flotats, A., Kolinger, G. D., Bullich, S., Perez-Martinez, E., Pagonabarraga, J., & Kulisevsky, J. (2026). Stage-dependent tau-PET signatures in Huntington’s disease revealed by [¹⁸F]PI-2620. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08003-0

Vancouver

Martinez-Horta S, Perez-Perez J, Puig-Davi A, Camacho V, Perez-Carasol L, Franch-Marti C, et al. Stage-dependent tau-PET signatures in Huntington’s disease revealed by [¹⁸F]PI-2620. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-08003-0

BibTeX
@article{MartinezHorta2026,
  author = {Martinez-Horta, Saul and Perez-Perez, Jesus and Puig-Davi, Arnau and Camacho, Valle and Perez-Carasol, Laura and Franch-Marti, Carla and Olmedo-Saura, Gonzalo and Fernandez-Leon, Alex and Flotats, Albert and Kolinger, Guilherme D and Bullich, Santiago and Perez-Martinez, Esther and Pagonabarraga, Javier and Kulisevsky, Jaime},
  title = {Stage-dependent tau-PET signatures in Huntington’s disease revealed by [¹⁸F]PI-2620},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-08003-0}
}
Kostenlos starten →